Company intelligence / Profile preview
L&J Bio
Seongnam-si, Gyeonggi-do, South Korealnjbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
L&J Bio is a South Korean biotechnology company specializing in the development of Natural Killer (NK) cell therapies for oncology. The company utilizes a proprietary platform for the mass production and activation of high-purity NK cells, aiming to provide effective allogeneic treatments for solid tumors and hematologic malignancies. Their lead candidate, L&J-NK, is currently being evaluated in clinical trials for its safety and efficacy in patients with advanced cancers. L&J Bio maintains its own GMP manufacturing capabilities to ensure the quality and scalability of its cell therapy products.
- Therapeutic areas
- Oncology
- Modalities
- NK cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on L&J Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L&J Bio.